Manulife: Record Core Earnings but Valuation Expansion and Asia Mixed Signals Prompt Hold

What happened

Manulife Financial had been rated BUY in mid-2025 based on a ~10.9x P/E, 4.1% dividend yield, strong LICAT 139%, and de-risking measures. New Q3 2026 results show record core earnings of C$2.125B, up 4% YoY, driven by Asia (up 17%), but reported net income fell 22% due to weaker alternative asset returns. Asia remains the growth engine, with Hong Kong and Japan performing well, but mainland China saw a sharp decline in APE sales, raising concerns about regional momentum. The Seeking Alpha article assigns a Hold rating, arguing that valuation expansion has outpaced underlying profitability growth, implying the stock is no longer cheap relative to earnings. This contrasts with the earlier BUY thesis predicated on a modest multiple and improving flows; key watch items—Asia sales quality and Global WAM alternatives performance—have turned negative.

Implication

The low valuation that underpinned the BUY case has dissipated; current multiples reflect optimism, leaving little margin of safety. Core earnings growth of 4% is modest and below the double-digit Asia growth, indicating other segments may be dragging; the 22% drop in reported net income highlights earnings volatility from alternative assets. The sharp APE decline in mainland China is a red flag against the Asia growth story, as China was a key market; Hong Kong and Japan strength may not fully offset this. Global WAM alternative returns weakness underscores the fee-income sensitivity; without durable inflows and steady performance, the compounding narrative is challenged. Therefore, until there is evidence of re-acceleration in Asia APE/NBV and stabilization in alternatives, a Hold is appropriate; existing holders may benefit from the dividend, but new capital should wait for a more attractive entry or clearer catalysts.

Thesis delta

The previous BUY thesis rested on a cheap valuation, strong capital, and Asia/WAM growth. New evidence shows the valuation has expanded to the point of being expensive, Asia growth is mixed with a sharp APE decline in China, and reported net income fell due to weaker alternative returns. Consequently, the thesis shifts from BUY to HOLD; the de-risking and capital return story remains intact but no longer offers sufficient margin of safety or momentum to warrant a BUY at current levels.